Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease.
Møller-Hansen M., Larsen AC., Toft PB., Lynggaard CD., Schwartz C., Bruunsgaard H.
Clinical Trial on Face & Skin, published in Ocul Surf (2020) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Ocul Surf (2020)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 33253910
- DOI
- 10.1016/j.jtos.2020.11.013
- Citations
- 54
Abstract (original English)
To evaluate the safety and feasibility of injecting allogeneic adipose-derived mesenchymal stem cells (ASCs) into the lacrimal gland (LG) as a treatment of aqueous deficient dry eye disease (ADDE). In this open-label, 5-visit clinical trial (baseline, treatment and weeks 1, 4 and 16) seven subjects with ADDE received one transconjunctival injection of allogeneic ASCs into the LG in one eye. The ASC product contained 22 million ASCs/ml and the injected volume was maximally 50% of the LG volume as determined on magnetic resonance imaging (MRI). Treatment related adverse events (AEs) were assessed at each visit (primary endpoint). Ocular Surface Disease Index (OSDI), tear osmolarity, tear film breakup time (TBUT), corneal staining (Oxford grade) and Schirmer's I test were assessed at each timepoint. No AEs related to the study treatment were observed. Mean follow-up time was 126 days after treatment. The mean OSDI score decreased from 58.9 ± 20.6 at baseline to 34.1 ± 21.6 (p < 0.002). In the study eye mean tear osmolarity decreased from 312.9 ± 10.4 to 291.6 ± 10.9 mosm/l (p < 0.002), mean TBUT increased from 3.7 ± 1.5 to 7.1 ± 1.9 s (p < 0.002), mean Schirmer's I test increased from 4.6 ± 0.7 to 8.1 ± 3.1 mm/5 min (p < 0.03), while mean Oxford grade showed a trend towards a decrease from 2.4 ± 0.7 to 1.3 ± 1 (p < 0.10). Our trial suggests that injection of allogeneic ASCs into t
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Oncologic safety of autologous fat grafting in head and neck cancer patients: A scoping review.
Systematic Review with a reported sample of 116 on Face & Skin, published in Med Oral Patol Oral Cir Bucal (2026) — summary generated from the PubMed abstract.
- 2026
- n = 116
Med Oral Patol Oral Cir Bucal - Level ASystematic ReviewEurope PMC
Stem cell-derived exosomes in tissue regeneration of oral and maxillofacial region: A systematic review
Systematic Review on Chronic Wound, published in Medicine (Baltimore) (2026) — summary generated from the PubMed abstract.
- 2026
Medicine (Baltimore) - Level AMeta-analysisPubMed
Stromal Vascular Fraction-Assisted Fat Grafting: A Systematic Review and Meta-analysis of Clinical Outcomes.
Meta-analysis on Face & Skin, published in Aesthetic Plast Surg (2026) — summary generated from the PubMed abstract.
- 2026
Aesthetic Plast Surg - Level ASystematic ReviewEurope PMC
Applications of Exosomes in Female Medicine: A Systematic Review of Molecular Biology, Diagnostic and Therapeutic Perspectives
Systematic Review on Face & Skin, Systemic / IV, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci2 citations - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Osteogenic and Biocompatibility Potential of Polylactic Acid-Based Materials: A Systematic Review of Human Primary Cells Studies
Systematic Review on Face & Skin, published in J Funct Biomater (2026) — summary generated from the PubMed abstract.
- 2026
J Funct Biomater